Search
for
Sort by
Research 23
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- The role of janus kinases in the treatment of autoimmune skin diseases
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- New therapies for alopecia areata
- Therapeutic Approach to Vaccine-Induced Ischemic Dermatopathy in a Pomeranian Dog with Refractory Alopecia
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
- Alopecia areata following COVID-19 vaccine: a systematic review
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- New and Emerging Therapies for Alopecia Areata
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Under Development JAK Inhibitors for Dermatologic Diseases
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- Review of Promising Off-Label Use of Deucravacitinib
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway